Trial Profile
A phase II, multi-center, open-label trial to evaluate the efficacy and safety of intravenous DAVANAT in combination with 5-fluorouracil when administered in monthly cycles as third- or fourth-line therapy for metastatic colorectal cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Galactomannan (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- 05 Mar 2012 Company (Galectin Therapeutics) added as trial sponsor as reported by ClinicalTrials.gov.
- 05 Mar 2012 Planned end date 1 Feb 2008 added added as reported by ClinicalTrials.gov.
- 04 Mar 2008 Survival data for all 20 patients has been reported in a Pro-Pharmaceuticals media release.